Andrew Huberman Slams ‘Peptides’ Media Coverage as a “Dog’s Breakfast,” Says Pharma Divide Fuels Black and Gray Markets

The thread shares Huberman's criticism of how media lumps peptides together inaccurately. Participants discuss tightening access to certain compounds and how large pharma companies push against gray market options. Some express frustration with sourcing difficulties while others point to ongoing loopholes and corporate motives.

• Huberman called broad peptide coverage a dog's breakfast that ignores regulatory differences
• Concerns raised about future restrictions on specific compounds like retatrutide
• Users note loopholes may keep some availability despite crackdowns
• Large pharma compensation and shareholder details highlighted as motivation against gray markets
• Sourcing described as increasingly difficult due to fear and regulatory pressure

Some believe loopholes will sustain access while others see sourcing becoming a real hassle from ongoing restrictions.

Nothing here is advice.